Adial Pharmaceuticals, Inc. Increase (Decrease) in Prepaid Expense
Adial Pharmaceuticals, Inc. (ADIL) reported Increase (Decrease) in Prepaid Expense of $418.77 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-30.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidExpense · last filed 2023-03-30
- Adial Pharmaceuticals, Inc. increase (decrease) in prepaid expense for the quarter ending 2022-12-31 was -$87.80K.
- Adial Pharmaceuticals, Inc. increase (decrease) in prepaid expense for the quarter ending 2022-09-30 was -$72.43K.
- Adial Pharmaceuticals, Inc. increase (decrease) in prepaid expense for the quarter ending 2021-12-31 was -$225.60K, a 136.02% decline year-over-year.
- Adial Pharmaceuticals, Inc. increase (decrease) in prepaid expense for the quarter ending 2021-03-31 was $3.85K, a 98.14% decline year-over-year.
- Adial Pharmaceuticals, Inc. increase (decrease) in prepaid expense for fiscal 2022 was $418.77K.
- Adial Pharmaceuticals, Inc. increase (decrease) in prepaid expense for fiscal 2021 was -$223.10K, a 173.42% decline from fiscal 2020.
- Adial Pharmaceuticals, Inc. increase (decrease) in prepaid expense for fiscal 2020 was $303.88K, a 881.65% increase from fiscal 2019.
- Adial Pharmaceuticals, Inc. increase (decrease) in prepaid expense for fiscal 2019 was $30.96K, a 93.88% decline from fiscal 2018.
| Period end | Increase (Decrease) in Prepaid Expense 1 month | Increase (Decrease) in Prepaid Expense 3 month | Increase (Decrease) in Prepaid Expense 6 month | Increase (Decrease) in Prepaid Expense 9 month | Increase (Decrease) in Prepaid Expense 12 month | Increase (Decrease) in Prepaid Expense 12 month as first filed |
|---|---|---|---|---|---|---|
| 2022-12-31 | -$87.80K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | -$160.23K derived: sum of 2 quarters · filed 2023-03-30 | $418.77K 10-K · filed 2023-03-30 | |||
| 2022-09-30 | -$72.43K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $506.57K 10-Q · filed 2022-11-14 | ||||
| 2022-06-30 | $579.00K 10-Q · filed 2022-08-15 | |||||
| 2021-12-31 | -$225.60K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | -$223.10K 10-K · filed 2023-03-30 | ||||
| 2021-09-30 | $2.50K 10-Q · filed 2022-11-14 | |||||
| 2021-03-31 | $3.85K 10-Q · filed 2022-05-16 | $630.24K derived: sum of 2 quarters · filed 2022-05-16 | $176.11K derived: sum of 3 quarters · filed 2022-05-16 | $101.45K derived: sum of 4 quarters · filed 2022-05-16 | ||
| 2020-12-31 | $626.39K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $172.26K derived: sum of 2 quarters · filed 2022-03-28 | $97.60K derived: sum of 3 quarters · filed 2022-03-28 | $303.88K 10-K · filed 2022-03-28 | -$303.88K 10-K · filed 2021-03-22 | |
| 2020-09-30 | -$454.13K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | -$528.78K derived: sum of 2 quarters · filed 2021-11-15 | -$322.51K 10-Q · filed 2021-11-15 | -$245.65K derived: sum of 4 quarters · filed 2021-11-15 | ||
| 2020-06-30 | -$74.66K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $131.62K 10-Q · filed 2021-08-12 | $208.48K derived: sum of 3 quarters · filed 2021-08-12 | $396.85K derived: sum of 4 quarters · filed 2021-08-12 | ||
| 2020-03-31 | $206.28K 10-Q · filed 2021-05-17 | $283.14K derived: sum of 2 quarters · filed 2021-05-17 | $471.51K derived: sum of 3 quarters · filed 2021-05-17 | $363.52K derived: sum of 4 quarters · filed 2021-05-17 | ||
| 2019-12-31 | $76.86K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-22 | $265.23K derived: sum of 2 quarters · filed 2021-03-22 | $157.25K derived: sum of 3 quarters · filed 2021-03-22 | $30.96K 10-K · filed 2021-03-22 | ||
| 2019-09-30 | $294.12K 10-Q · filed 2020-11-13 | $188.37K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13 | $80.39K derived: sum of 2 quarters · filed 2020-11-13 | -$45.91K 10-Q · filed 2020-11-13 | ||
| 2019-06-30 | -$107.98K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | -$234.27K 10-Q · filed 2020-08-13 | ||||
| 2019-03-31 | -$126.29K 10-Q · filed 2020-05-14 | |||||
| 2018-12-31 | $505.96K 10-K · filed 2020-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |